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Background: Lymphatic filariasis (LF) occurs when filarial parasites are transmitted to humans through mosquitoes.
The filarial worms affect the lymphatic system which leads to abnormal enlargement of body parts, chronic pain,
disability, and social discrimination. In 1999, a commitment was made to eliminate LF from the Pacific Region by
2010. The Pacific Program to Eliminate LF began, with Vanuatu being one of the 16 endemic countries included in
this program.
Methods: In 1997/1998 a LF prevalence baseline survey was conducted to determine the need for mass drug
administration (MDA) in Vanuatu. In 1999, the Vanuatu Lymphatic Filariasis Control Program was established, and
nationwide MDA was implemented from 2000 to 2004. LF prevalence was collected during the MDA through
sentinel site and spot check surveys, and after 5 years of MDA. MDA implementation methods included health
worker training, social mobilization, and culturally appropriate health promotion strategies.
Results: LF prevalence at baseline was 4.79%; after MDA this declined to 0.16% in 2005/2006. Average MDA coverage
ranged from 75.5–81.5% across 5 years. All three evaluation units surveyed in 2005/2006 were below the 1% threshold
required to stop MDA.
Conclusions: The LF Control Program between 1997 and 2006 was successful in reducing LF prevalence to <1%.
High MDA coverage was a critical component of this success. This period of the Vanuatu LF Control Program
played an important role in helping to eliminate LF in Vanuatu.
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Lymphatic filariasis (LF) occurs when filarial parasites
are transmitted to humans through mosquitoes which
pick up the microfilarial stage from the peripheral blood.
The adult filarial worms reside in, and affect, the lymphatic
system and can result in abnormal enlargement of body
parts, chronic pain, disability, and social stigmatization [1].
In 2015, LF was endemic in 55 countries [2]. There con-
tinues to be an estimated 67.88 million cases of LF world-
wide, including 36.45 million microfilaria (Mf) carriers,* Correspondence: ftaleo@vanuatu.gov.vu
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of lymphoedema or elephantiasis [3].History of LF in the Pacific
LF is a significant public health issue in the Pacific Region
[4]. In 2000, 16 of the 22 Pacific countries or territories
were classified as endemic and in need of interventions to
eliminate LF (Fig. 1) [5].
In 1999, the World Health Organization (WHO),
Western Pacific Regional Office (WPRO), together with
the Secretariat for the Pacific Community (SPC) and
public health officials from Pacific Countries initiated
the Pacific Program to Eliminate LF (PacELF) in Pacific
Countries and Territories [6]. PacELF was a WHO led andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Fig. 1 LF endemicity in the Pacific in 2000
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egy in the 1970s. PacELF focused on:
 A community-based and self-help driven approach
 Regional collaboration to benefit the entire Pacific
family
 Pacific island country ownership
 Operational flexibility—each country chose its own
mass drug treatment operational strategy, including
customized social mobilization and information,
education, and communication activities
 A simple core package of activities—provision and
promotion of mass drug administration (MDA),
morbidity treatment, and vector control including
the use of mosquito nets when relevant
 Integration into existing health services [7].History of LF in Vanuatu
Vanuatu was one of the 16 endemic countries included
in PacELF [8]. Vanuatu consists of an archipelago of 83
islands located between 12° to 21°S and 166o to 171°E.
The islands are divided into six provinces known from
north to south as Torba, Sanma, Penama, Malampa,
Shefa, and Tafea (Fig. 2). Based on the 2009 census the
population of Vanuatu was 234,023. Mean population
density was 19 persons per square kilometer, rangingfrom 11 in Sanma and Torba Province to 52 in Shefa
Province [9].
Prevalence of LF in Vanuatu was first recorded in 1927.
Buxton [10] reported results of a LF survey (n = 318 males
tested over 12 years of age) in 16 islands of whom 100
(31%) were found to be Mf positive. Byrd and St Amant
[11] reported surveys of Mf prevalence in 1943–1944 in 396
people (343 > 15 years and 53 < 15 years). Prevalence was
24.5% in adults and 3.8% in children. Males had a higher in-
fection rate of 25.6% compared to 15.1% in females. Of
those sampled, 183 were plantation workers who had lived
in Espiritu Santo for <6 months but originated from 12
islands throughout Vanuatu. Among long-term residents,
33.6% were positive (n = 85 tested) in two villages on
Espiritu Santo Island, and 0% (n = 104 tested) on two
small islands offshore from Santo. A survey published
in 1971 reported 32 cases of elephantiasis in a popula-
tion of 2120 (1.5%) around Norsup in northern Malekula
Island (Malampa Province), with the youngest case in a
14 year old [12]; the prevalence of microfilaria at night
was 12.7% (n = 63). In 1978–1979, a survey of 7137 people
on 12 islands from north to south found prevalence of
10% or above on the islands of Malekula and Ambrym
(Malampa Province) and Epi (Shefa Province), 7% in
Torres (Torba Province) and the remainder at 6% or
below [13]. Elephantiasis cases (19 in total) were observed
only on Banks, Santo, Maewo, and Efate Islands. MDA
Fig. 2 Vanuatu province boundaries
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seven islands; Santo (Sanma Province), Hiu and Gaua
(Torba Province), Malekula (Malampa Province), Erro-
mango, Aniwa and Aneityum (Tafea Province), al-
though details of the population numbers are not given
[13]. In some areas MDA was combined with vector con-
trol (DDT spraying) or DDT spraying alone was done,
and the reductions in prevalence and density of Mf
were dramatic. However, elimination was not achieved,
with transmission persisting on Malekula, Santo, Pente-
cost, and Epi Islands in the mid-1980s. The varying geo-
graphical prevalence of LF in Vanuatu is thus a result of
environmental factors such as temperature variations and
previous control methods on some islands.
There were no other significant LF prevalence studies
conducted or programs implemented to specifically treat
and eliminate LF in Vanuatu until 1997. There was how-
ever, a malaria control program in Vanuatu focused pri-
marily on the use of insecticide-treated bed nets (ITN) to
protect against mosquito bites. Given that the same species
of mosquito Anopheles spp. transmits both malaria and LF
in Vanuatu, this likely had some impact on LF prevalence.
In 1999, with PacELF support, the Vanuatu National LF
Control Program was established within the Malaria andOther Vector Borne Diseases Control Unit (VBDCU) of
the Vanuatu Ministry of Health (Ichimori K: Vanuatu na-
tional filariasis programme plan of work for 1998, unpub-
lished). The program’s aim was to (1) assess the prevalence
of filariasis in Vanuatu and treat positive cases and (2) elim-
inate the risk of LF to the population through MDA of
albendazole (GSK Donation Program) and DEC, as well as
vector control (WHO: Application from the ministry of
Health of Vanuatu to support a national programme to
eliminate lymphatic filariasis in 1998, unpublished).
This is the first published paper presenting comprehen-
sive results of Vanuatu’s LF Control Program, building on
Fraser et al.’s (2005) evaluation of mid-term results [14].
This paper describes LF prevalence before MDA, results
from sentinel site and spot check surveys during MDA,
and LF prevalence after 5 years of MDA. This paper also
details the methods used to effectively deliver MDA. The
post-MDA surveillance period and validation of elimin-
ation in 2016 through the Vanuatu Ministry of Health and
PacELF efforts are described separately, together with
morbidity surveys, in comparison papers.
Methods
The aim of this paper is to evaluate the impact of
Vanuatu’s LF Control Program on filariasis in Vanuatu
from 1997 to 2006. Vanuatu’s LF Control Program con-
sisted of three key phases, [6] namely:
1. Baseline mapping phase: the A survey of LF
prevalence, conducted to determine the need for MDA
2. Intervention Phase which included:
◦MDA annually over 5 years
◦Health promotion through distribution of
morbidity posters, morbidity treatment kits,
promotion of mosquito net usage
◦The B survey of LF prevalence in specific sentinel
sites, implemented after two MDA rounds
◦Periodic spot checks
3. Stop MDA Phase: the C survey of LF prevalence, to
determine whether prevalence was below 1% for
MDA to be stopped
A survey (baseline survey)
The A survey was conducted in 1997/1998 to ascertain LF
prevalence in Vanuatu. Samples were collected from per-
sons >2 years of age in 51 villages throughout the 6 prov-
inces of Vanuatu. The number of villages sampled per
province was based on proportional population distribution
by province from the 1989 National Census (Table 1).
Convenience sampling was used at the village/house-
hold level, with residents (>2 years of age) of selected vil-
lages invited to participate. From the 51 villages, 4363
people were tested by Binax Immunochromatographic
Test (ICT) to detect circulating antigen to Wuchereria
Table 1 Proportion of population sampled
Province Population per
provincea
% of total population Total examined by
province
% of total examined
by province
No. of villages sampled
per province
Torba 5985 4.2 227 4.4 4
Sanma 25542 17.9 833 16.3 7
Penama 22281 15.6 784 15.3 8
Malampa 28174 19.8 894 17.5 8
Shefa 38023 26.7 1429 27.9 14
Tafea 22414 15.7 952 18.6 10
Total 142419 100 5119 100 51
a1989 National Census Date Source: [16]
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slides at night to detect the presence of Mf. Blood slides
were stained with Giemsa and read at the VBDCU in Port
Vila. From the sample population, 3573 people received
both ICT and Mf tests [15]. All antigen-positive and Mf-
positive cases were treated with DEC+ albendazole [16].
Mass drug administration
MDA is the recommended strategy required to suppress
Mf numbers and transmission of the parasite over the life
of the adult parasites, approximately 5 years [6]. The A
survey in 1997/1998 demonstrated that LF prevalence was
greater than 1% in Vanuatu. This level of prevalence quali-
fied the country for free drug treatment, which was do-
nated by WHO and GlaxoSmithKline to facilitate the
elimination process. The Vanuatu Ministry of Health car-
ried out five rounds of MDA nationwide from 2000 to
2004 [16]. MDA treatment included one dose of drugs
(DEC and Albendazole) per person, per year using directly
observed treatment (DOT). As weight was not always
known, age was used to determine DEC dosage per per-
son. 50 mg tablets were given as follows : 2–9 years of age,
2 tablets; 10–19 years of age, 5 tablets; 20–29 years of age,
7 tablets; 30–59 years of age, 8 tablets; >60 years, 7 tab-
lets). Albendazole dosage was 400 mg per person. Preg-
nant women, those under 2 years and very sick people
were excluded. MDA coverage of the national population
was reported every year against the registered population,
the eligible population, and the national population [6].
The latter denominator is used in this paper.
MDA program implementation
Social mobilization and IEC (information, education and
communication) strategy
The MDA communication strategy was based on a Know-
ledge, Attitudes and Practice (KAP) survey conducted a
couple of months before the first round of MDA began.
This helped to ascertain knowledge gaps on the disease and
was used to inform the development of the IEC materials
such as posters, leaflets and t-shirts. A second KAP survey
was conducted after two MDA rounds to measurecommunity opinion and levels of acceptance toward MDA
to help inform future strategies.
Two training workshops were carried out prior to the
MDA for nurses, nurse aides, and village chiefs. The aims of
the workshops were to plan MDA dissemination strategies
including social mobilization and communication strategies,
prepare finances and conduct registration training.
Communication strategies began 2–3 weeks prior to
each round of MDA to prepare the community for
MDA. Working closely with the village chiefs, commu-
nity leaders and church leaders was critical to the suc-
cess of the program. In addition to including the village
chiefs in the training workshops, province level staff or-
ganized official meetings with the chiefs using traditional
custom approaches including ceremonies, drinking the
local kava drink, killing and eating pigs, and gifting of
mats. Community engagement in the weeks leading up
to MDA included community talks, distribution of infor-
mation leaflets, radio drama, and Q&A sessions with ex-
perts. Pictures were found to have a strong impact, so
posters were developed with pictures of persons with
signs and symptoms of LF.
During MDA, all the health workers continuously
followed-up on any refusal cases and tried their best to
address this to ensure high coverage. Melanesian culture
hold health workers and community leaders in high es-
teem, and this assisted to optimize community accept-
ance towards MDA.
Drug supply chain, storage, and distribution
The donated drugs were ordered through WHO, were
coordinated by the PacELF office, and were shipped to
Vanuatu. Customs processing and storage fees were paid
by the program to customs. Everything was pre-packed
into health zones packages at national level and then
distributed by the program. As the drugs did not require
refrigeration, they were stored in government medical
stores and health centers until distributed by nurses (as
part of their community outreach role) and nurse aides.
While the nurses distributed the drugs, the nurse aides
supported the social mobilization efforts in the
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MDA. About 200 nurses took part in the annual MDA
with 750 persons on average treated by each nurse,
working over a 2–3-month period. 1–2 nurses would re-
main in clinics to see the normal patient load. MDA was
door to door or office to office. In addition, children
were treated in schools and in the community, and fixed
posts were set-up over a period of 2 weeks after MDA.
DOT was always enforced with provision of cups and
water. Supervisors emphasized strict adherence to the
DOT protocol. Travel allowance (1700 vatu, approxi-
mately USD15, the standard government rate) was given
to nurses and nurse aides if they had to sleep overnight,
and accommodation and transport costs were paid. In
the urban setting of Port Vila, public health officials and
health workers delivered the treatments with volunteers
supporting registration and recordings. All unused drugs
were returned to province level and stored in pharma-
cies for routine treatment and use in surveys.Supervision
Supervision was led by the province level malaria supervi-
sors and other public health provincial level managers. The
supervisor’s role was to check in with each MDA team
every 2–3 days. Supervisors would carry extra registration
books and medicines, follow-up on any refusals, and com-
pare numbers treated to the target population.Adverse events
Communication included information on what to expect
in terms of minor side effects. To address potential ser-
ious adverse events (SAEs), forms were distributed every
year to province level. Only one case was ever reported,
but was found not to be linked to treatment.Program monitoring
Coverage was the key indicator calculated every year.
Treatments were recorded in registration books which
were shipped back to national level after each MDA.
Books were numbered with a special code and receipt of
registration books was carefully monitored, including
tracking down of missing books. Front page summary
sheets allowed for quick calculation of coverage rates
and then all data was entered into a database. A cover-
age survey conducted after two rounds of MDA vali-
dated the quality of routinely reported data.Vector control
During MDA, the VBDCU also actively engaged in malaria
control programs including distribution of ITNs, education
on the use of nets, and indoor residual spraying [17].B survey (sentinel site survey) and spot check surveys
During the MDA period, LF prevalence was monitored
using ICT blood tests and Mf night blood slides at senti-
nel sites (B survey) and spot check sites.
B survey
Sentinel sites were chosen from A survey results, whereby
the two villages with the highest antigen prevalence within
the four highest endemic provinces were selected. These
sites were Sola and Mosina Village (Torba Province), Sakau
and Wanur villages (Penama Province), Orap and Unmet
villages (Malampa Province), and Port Resolution and South
River villages (Tafea Province) [14]. In 2002, after two
rounds of MDA, the B survey was conducted to evaluate
whether MDA was decreasing antigen prevalence in these
villages of high endemicity [14]. All individuals >10 years
were invited to have an ICT blood test (except in Port Reso-
lution where only 300 were examined). Night blood slides
for Mf were taken from antigen-positive persons only. Slides
were prepared with 60 ul of blood, dried, stained with
Giemsa, and examined at the VBDCU in Port Vila. Sentinel
sites were surveyed again in 2005/2006, except for Malampa
Province.
Along with the ICT blood test, individuals were also
asked about their mosquito net usage. The following two
questions were asked “do you usually use a bednet?” and
“did you use a bed net last night?”.
Spot check surveys
As sentinel sites may receive more programmatic attention
than other sites, additional spot checks were conducted to
determine if further rounds of MDA were needed at certain
villages or islands. In 2002, spot check surveys were con-
ducted in persons >10 years in Redcliffe village (Penama)
and Lingarak village (Malampa). Spot checks were also con-
ducted at Vila Central Hospital (Shefa) and Santo Northern
District Hospital (Sanma) for people receiving malaria slide
tests. In 2003, spot checks were conducted in Lolowai
Hospital (Penama) and Norsup Hospital (Malampa), and
repeated again in Vila Central Hospital and Santo
Northern District Hospital. In 2004, spot checks were
conducted in the villages of North Ambrym (Malampa).
C survey (transmission assessment survey or TAS 1)
In 2005 and 2006, after five rounds of MDA, the C survey
was conducted in villages from three evaluation units (EU)
created from Vanuatu’s six provinces. These EUs were (1)
Torba, Sanma and Malampa; (2) Penama and (3) Shefa and
Tafea (note: the urban areas of Luganville, Santo Island,
Sanma Province, EU1 and Port Vila, Efate Island, Shefa
Province, EU3, were excluded from the sampling frame).
Combination of provinces to EUs and sampling frame were
determined based on baseline antigen prevalence [18]. If
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dence limit <2%) in each EU, then MDA could be stopped.
C survey sampling used systematic selection of clusters
with probability proportional to village size through a
method modified from UNICEF’s multiple indicator cluster
survey design [19]. Target sample per EU was 30 clusters of
15 households (i.e. 450 households with estimated 2700 per-
sons at 6 per household). Total target national sample was
90 clusters i.e. 1350 households or ~7100 persons. Sample
clusters were systematically selected by a random start from
villages listed with their number of clusters estimated from
village size using census information. Cluster size of 15
households was chosen to (1) keep overall numbers of per-
sons tested within reasonable limits for a one-day visit and
(2) prevent the need to combine villages together due to
many villages being quite small, but with large households.
Respondents were tested for antigen prevalence through
ICT and were asked about mosquito net usage. Night blood
slides for Mf were taken from antigen-positive persons only.
Persons ages 1 year or older were eligible to participate. The
C survey also collected information about mosquito net
availability and use for each participant.
Statistical analysis was carried out using Microsoft
Excel and STATA 14. Data on participant characteristics
were analyzed using descriptive statistics. Comparisons
involving categorical variables were conducted with chi-
squared tests, and exact binomial confidence intervals
were used to analyze proportional statistics.
Results
A survey
A survey data was collected in 1997/1998. A total of
4363 ICT samples and 4330 Mf samples were collected
from persons of all ages in 51 villages throughout the six
provinces of Vanuatu. 4.8% of ICT samples were
antigen-positive, and 2.5% of Mf samples were Mf-
positive. Of the 3573 people who had both the ICT and
Mf test, 5.8% were ICT positive, and 3.2% were Mf posi-
tive [15]. Six Mf positive cases were ICT negative.
Penama Province had the highest antigen prevalence with
14.9%, followed by Torba Province with 10.2%, MalampaTable 2 Antigen-positive and Mf positives—provincial level in 1997
Province Total ICT tested Antigen positive % Total Mf slide tested M
Torba 59 10.2 227
Sanma 371 0.3 833
Penama 776 14.9 723
Malampa 846 7.1 894
Shefa 1363 0.1 640
Tafea 948 2.5 952
Total 4363 4.8 4269
Data source: [16]Province at 7.1% and Tafea Province 2.5%. Shefa Province
and Sanma Province had low levels of antigen positives: 0.1
and 0.3%, respectively. Prevalence of Mf was generally two
to three times lower than antigen prevalence (Table 2).
The spatial distribution of antigen-positive cases in each
village surveyed can be found below (Fig. 3). More than half
of the 51 villages (n = 28) had no positive cases. There were
eight villages with greater than 10% antigen prevalence: two
villages in Torba Province, four in Penama Province, one in
Malampa Province, and one in Tafea Province.
Age and gender
Age-specific antigen prevalence in 1997/1998 showed
5.19% of children aged 3 to 10 years were antigen positive
(n = 212). Antigen prevalence in the over 50 age group was
between 10 and 11.5% antigen-positive (n = 380) (Table 3).
Gender-related antigen prevalence (Table 4) showed males
with a significantly higher prevalence than females: 5.8% in
males and 3.9% in females (chi-square = 8.14 p = 0.004).
Mass drug administration
After the A survey, MDA was conducted across six
provinces from 2000 to 2004. With the exception of
Torba Province in 2002, province level treatment cover-
age of MDA was between 75.5 and 81.5% [18] (Table 5).
B survey and spot check surveys
Sentinel site survey
In 2002, the B survey was conducted in Sola and Mosina
(Torba Province), Sakau and Wanur (Penama Province),
Orap and Unmet (Malampa Province), and Port Resolution
and South River (Tafea Province). Survey results showed a
decline in antigen prevalence in all sentinel sites compared
to 1997/98. In 2005/2006, all sentinel sites except for
Malampa Province were tested again. Antigen prevalence
was 0% in all sites except for Sakau (6.4%) and Wanur
(2.2%) (Penama Province). Overall, sentinel site results
showed MDA was having an impact and decreasing antigen
prevalence in high endemicity villages (Fig. 4). In terms of
mosquito net usage, 75.5% of respondents answered “yes”
when asked if they usually use a mosquito net (n = 1168)./98
f Positive % Total Tested both ICT
and Mf slide
Antigen positive % Mf positive %
3.1 59 10.2 5.1
0.2 370 0.3 0
7.9 776 15.0 9.2
3.6 846 7.1 3.8
0.2 574 0.2 0.2
0.7 948 2.5 0.7
2.5 3573 5.8 3.2
Fig. 3 Antigen prevalence in Vanuatu villages 1997/1998
Table 3 1997/1998 age and antigen prevalence
Age group No. negative No. positive positive (%)
3 to 10 201 11 5.19
11 to 15 346 11 3.08
16 to 20 702 21 2.90
21 to 30 1116 46 3.96
31 to 40 642 45 6.55
41 to 50 368 20 5.15
51 to 60 211 24 10.21
61 to 70 123 15 10.87
70+ 46 6 11.54
Grand total 4154 209 4.8
No data (n = 208). Data source: [16]
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you usually use a bednet?” and “did you use a bednet last
night?” so it can be assumed that those who said that they
“usually” use a bednet, slept in it the night before).
Spot check surveys
In 2002, spot check survey results showed Redcliffe Village
(Penama) had 40% antigen-positive (n = 129 tested),Table 4 1997/1998 gender and antigen prevalence
Gender No. negative No. positive % positive (%)
F 2267 93 3.9
M 1887 116 5.8
Grand total 4154 209 4.8
No data (n = 208). Data source: [16]
Table 5 MDA coverage by province and year
Province MDA coverage
2000 (%) 2001 (%) 2002 (%) 2003 (%) 2004 (%)
Torba 80.0 82.8 56.2 86.1 84.4
Sanma 77.2 73.5 76.2 80.2 73.4
Penama 90.5 82.6 78.8 80.8 79.1
Malampa 88.4 84.5 85.5 77.2 81.0
Shefa 81.8 86.7 78.4 81.8 82.1
Tafea 70.5 69.1 72.7 76.7 65.7
Average coverage 81.5 80.3 78.2 79.6 75.5
Data source: [16]
Estimated census population [6] were used as denominators to avoid
underestimating population coverage
Table 6 LF prevalence 1997/1998 and 2005/2006
Particulars A survey 1997/1998 C survey 2005/2006
No. of villages tested 51 90
No. tested for antigen 4363 7657
No. antigen-positive 209 (4.79%) 12 (0.16%)
No. tested for Mf 4269 12a
No. Mf-positive 106 (2.48%) 0
aNote: only those antigen-positive were tested for Mf in 05/06
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tested), Vila Central Hospital (Shefa) 3% antigen-positive
(n = 254 tested), and Santo Northern District Hospital
(Sanma) 2% antigen-positive (n = 168 tested).
In 2003, Santo Northern District Hospital showed
4.1% antigen-positive (n = 73 tested) and Vila Central
Hospital 0% antigen-positive (n = 89 tested). Spot check
surveys were also conducted in Lolowai Hospital
(Penama) with 7.8% antigen-positive (n = 154 tested),
and Norsup Hospital (Malampa) 13.5% antigen-positive
(n = 74 tested). In 2004, spot check monitoring in the
villages of North Ambrym (Malampa) found 19.2%
antigen-positive (n = 551 tested). Based on this result,
another three rounds of MDA were conducted in North
Ambrym villages (1999 census population: 3899).
C survey (TAS 1 survey)
In 2005/2006 C survey results in persons aged 1 year
and above showed that antigen positive prevalence had
dropped from 4.8% in 1997/1998 to 0.16% in 2005/2006
(0.274 upper 95% confidence limit) (Table 6). There were
no Mf positive cases found.Fig. 4 % antigen-positive for Vanuatu across eight sentinel sites from
1997/1998, 2002 and 2005/2006C survey evaluation unit results are described below.
In EU1, antigen prevalence was 0.17% (n = 2351 tested).
EU2 had 0.34% antigen prevalence (n = 2353 tested),
and EU3 had no antigen-positive cases (n = 2953 tested)
(Table 7). For each EU, prevalence (and upper 95% con-
fidence interval) had fallen to under the 1% threshold
required to stop MDA. This reduction in antigen preva-
lence can be seen when comparing EU prevalence in
1997/1998 with 2005/2006 (Fig. 5).Age and antigen prevalence
Age-specific antigen prevalence in 2005/2006 reduced
in all age groups compared with 1997/1998. In 2005–
2006, there were no antigen-positive cases under
5 years (n = 1166), 6–10 years (n = 1461) or 11–15 years
(n = 1041). Antigen prevalence was below 0.61% for
ages 21–60 years (n = 2919). There was no antigen-
positive case for 61+ years (n = 298) (Fig. 6).Gender and antigen prevalence
Gender-specific prevalence in 2005/2006 showed no
significant difference between male and female, with
both genders showing a reduction to less than 0.3%
in prevalence compared with 1997/1998 (Fig. 7).Table 7 Antigen-positive prevalence–EU level in 2005/2006
(EU) Province Number
tested
Antigen positive Upper 95% binomial
confidence interval %n %
1 Torba 236 4 1.69
Sanma 769 0 0.00
Malampa 1346 0 0.00
Total EU 1 2351 4 0.17 0.44
2 Penama 2353 8 0.34
Total EU 2 2353 8 0.34 0.67
3 Shefa 1689 0 0.00
Tafea 1254 0 0.00
Total EU 3 2953 0 0.00 0.13
Total population
sampled
7657 12 0.16 0.27
Data source: [16]
Fig. 5 Evaluation units and antigen prevalence in 1997/98
and 2005/2006
Fig. 7 Gender-specific antigen prevalence in 1997/1998
and 2005/2006
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The C survey also collected information about mosquito
net availability and use. The survey found 63% of re-
spondents said they had a bed net, and most of these re-
spondents reported sleeping under a net. The small
number of positives in the C survey precluded further
analysis of the relationship between antigen positivity
and net use after MDA.
Discussion
This study evaluated the impact of the LF control program
in Vanuatu from 1997 to 2006. The A survey conducted
in 1997/1998 showed prevalence of LF in Vanuatu was
4.79%. Notwithstanding limitations of convenience sam-
pling within selected villages, the A survey showed that LF
prevalence was more than the 1% required to justify the
need for a specific LF control program. The A survey re-
sults reflected a typical age-specific prevalence curve and
higher prevalence in males than females. Lower preva-
lence in females is a pattern that has been observed world-
wide and may be due to differential exposure, increased
resistance, or physiological factors [20]. The results of the
A survey have been presented in summary form pre-
viously in program reports [6, 16], and a summary
publication [21].
MDA was implemented in Vanuatu from 2000 to 2004
using a combination of DEC and Albendazole. AverageFig. 6 Age-specific antigen prevalence in 1997/1998 and 2005/2006MDA coverage ranged from 75.5 to 81.5% across the
5 years. The success of MDA is often measured by how
effectively it is implemented on the ground. Factors inte-
gral to this include the dissemination of culturally appro-
priate, evidence-based community awareness strategies,
development of trust, appropriate training, easy access to
treatment through numerous channels, and quality data
collection and analysis [22]. These were all the factors
found to influence the high level of MDA coverage in
Vanuatu. Specifically, the following strategies were seen as
crucial elements:
1) Awareness strategies used before MDA, such as
posters and leaflets with clear, visual messages on
the need to take medicine, side effects, the disease
and transmission
2) MDA being implemented by the health workers who
had established relationships with their community
and made sure to follow-up on non-treated cases
3) Engaging with community leaders to ensure
culturally appropriate strategies that promoted
medicine compliance.
The C survey followed the PacELF guidelines in place
at the time [6]. The survey was conducted in all ages in
clusters randomly selected as proportional to population
size, with a target threshold of 1% MDA prevalence. In
Vanuatu, because of the variable prevalence at the start
of the program, there was a concern that parts of the
country might not be ready to stop MDA in 2006. How-
ever, the results from the C survey demonstrated that
the threshold of <1% antigen prevalence across each EU
had been met. Although all EUs passed the C survey
threshold, the program proactively targeted a remaining
hotspot area of higher prevalence in North Ambrym in
Malampa Province (part of EU1) through three add-
itional rounds of targeted MDA after 2006.
Regarding age-specific prevalence, if transmission had
been interrupted in Vanuatu one would expect the age-
specific curve to shift to the right, showing persistence
Allen et al. Tropical Medicine and Health  (2017) 45:8 Page 10 of 11of infection in older persons infected some time ago,
and no new infection in young people. There is some
evidence of that in the C survey results, but overall too
few positives in 2005/06 to compare age groups.
Vanuatu is fortunate in being located at the fringe
of the range of Anopheles transmission; since this
mosquito is also the vector of malaria, the efforts of
the VBDCU have assisted in eliminating LF as well.
This is also demonstrated by the high usage of mos-
quito nets as reported in both the B survey and C
survey results.
The huge efforts of the LF Control Program and the
MDA coverage report show that the program success-
fully achieved low prevalence in 2005/2006. Further
study of areas of remaining transmission after MDA
may be useful to the other countries in the region and
will be reported separate to this paper.
Conclusions
The LF Control Program during 1997–2006 demonstrated
an important contribution towards LF elimination. This
paper showed that MDA successfully suppressed LF anti-
gen prevalence in Vanuatu to below 1% in 2006. Evaluation
of the next stage of Vanuatu’s elimination program, the
post MDA surveillance period after 2006, and documenta-
tion of governance, partnerships and community engage-
ment will be reported in companion papers to provide
further insight and learning from Vanuatu’s LF Control
Program, as well as PacELF and their achievements
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